Liver transplantation and nonalcoholic steatohepatitis: the state of the art

Stefano Gitto1,4, Nicolò Mannelli1, Andrea Tassi2, Filippo Gabrielli2, Fabio Nascimbeni2, Pietro Andreone2,3

1 Department of Experimental and Clinical Medicine, University of Florence, Florence 50121, Italy.
2 Division of Internal Medicine and Metabolism, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena 41126, Italy.
3 Chief of postgraduate school of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, Modena 41126 Italy.
4 Coordinator of MEDITRA (“MEtabolic Disorders after liver TRAnsplantation”) Research Group (www.meditra.org).

Correspondence to: Prof. Andreone, Division of Internal Medicine and Metabolism, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Via Pietro Giardini 1355, Modena 41126, Italy. E-mail: pietro.andreone@unimore.it

How to cite this article: Gitto S, Mannelli N, Tassi A, Gabrielli F, Nascimbeni F, Andreone P. Liver transplantation and nonalcoholic steatohepatitis: the state of the art. Metab Target Organ Damage 2022;2:7. https://dx.doi.org/10.20517/mtod.2022.04

Received: 7 Jan 2022 First Decision: 14 Feb 2022 Revised: 10 Mar 2022 Accepted: 1 Apr 2022 Published: 18 Apr 2022

Academic Editor: Amedeo Lonardo Copy Editor: Tiantian Shi Production Editor: Tiantian Shi

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents one of the most diffuse liver diseases worldwide. It is a condition ranging from liver steatosis to non-alcoholic steatohepatitis (NASH) and NASH-related cirrhosis. Recently, the term metabolic dysfunction-associated fatty liver disease has been proposed in place of NAFLD, accenting the metabolic and cardiovascular risks that accompany hepatic disease. In the last decades, NASH and NASH-related cirrhosis have been the fastest growing indications for liver transplantation (LT), and they will probably overcome the other indications in next future. After LT, recipients show an important increase in body weight due to a greater caloric intake, partially because of the metabolic influence of immunosuppressant drugs, favoring the development of diabetes mellitus, dyslipidemias, and arterial hypertension. These metabolic complications will, in turn, elevate cardiovascular risk in this population. In this review, we analyze the main metabolic challenges of both pre-and post-LT periods.

Keywords: Non-alcoholic steatohepatitis, liver transplantation, diabetes, metabolic syndrome, cardiovascular risk, graft survival
INTRODUCTION

Liver transplantation (LT) represents a consolidated therapy for acute liver failure, decompensated cirrhosis, and hepatocellular carcinoma (HCC)\(^1\).

The transplantation scenario has deeply changed over time. In industrialized countries, hepatitis B- or C-related cirrhosis is constantly decreasing thanks to the development of vaccine campaigns or new direct-acting antivirals, respectively\(^2,3\). Conversely, non-alcoholic steatohepatitis (NASH), alcoholic liver disease, and HCC are becoming leading indications for LT\(^4\).

NAFLD is a condition ranging from “simple” steatosis (NAFL) to a necro-inflammatory variant, named NASH, that may eventually progress to NASH-related cirrhosis and HCC (also in pre-cirrhotic stage). Notably, NAFLD and NASH are hepatic expressions of a systemic disorder\(^5,6\).

The term metabolic dysfunction-associated fatty liver disease has been recently proposed in place of NAFLD, indicating the metabolic and cardiovascular (CV) risks that accompany the hepatic disorder\(^7\).

Singh \textit{et al.}\(^8\) analyzed 11 cohort studies including 411 subjects with biopsy-proven NAFL (\(n = 150\)) and NASH (\(n = 261\)). Among 2145.5 person-years of follow-up evaluation, 33.6% of subjects showed a fibrosis increase, 43.1% displayed stable fibrosis, and 22.3% had a decrease in fibrosis. The annual fibrosis progression rate in patients with NAFL was 0.07 stages, while patients with NASH had 0.14 stages. In other words, patients with NAFL showed one stage of progression over 14.3 years and those with NASH one stage of progression over 7.1 years.

Remarkably, the increasing incidence of both obesity and type 2 diabetes mellitus (DM2) well explains the growing occurrence of NASH-related cirrhosis itself\(^9\).

Available data clearly indicate that in future decades NASH will be the main clinical issue for both hepatologists and transplantologists. Coherently, the United Network for Organ Sharing (UNOS) and the European Liver Transplant Registry reported that NASH has been the fastest growing indication for LT in the last 20 years in North America and Europe\(^10,11\).

In 2018, NASH was the second main indication for adult LTs in North America (1321, 21.5%)\(^10\), and NASH-related cirrhosis accounted for 8.4% of European LTs in 2016 (vs. 1.2% in 2002)\(^11\).

Remarkably, NAFLD is a chief cause of cirrhosis and HCC (also in the pre-cirrhotic stage), and it represents the fastest growing cause of HCC in both Europe and the United States\(^12,13\).

In the European context, NASH represents 4% of indications for LT, and among whom, one-third showed a liver disease complicated by HCC\(^14\). In the United States, NASH is the most rapidly increasing cause of HCC among patients waiting for LT. In particular, NASH-related HCC accounted for 0/472 in 2002, 41/1013 (4.0%) in 2007, and 81/1336 (6.0%) in 2012, reaching 16.2% in 2016\(^11,15\).

Interestingly, NASH-related cirrhosis is also the fastest rising LT indication for acute-on-chronic liver failure (ACLF)-related hospitalization and use of hospital resources\(^16\). From 2006 to 2014, ACLF as LT indication increased by 24% with a 63% growth in NASH (from 3.5% to 5.7%)\(^16\).
Patients with NASH-cirrhosis, NASH-related HCC, and NASH-related ACLF increasingly require LT\textsuperscript{[17]}. In fact, Parikh \textit{et al.}\textsuperscript{[18]} predicted an increase in NASH as an indication for LT in the United States of 55.4\% by 2030.

After LT, recipients frequently experience a noteworthy surge in body weight due to an increase in caloric intake\textsuperscript{[19,20]}. Diabetes mellitus, hyperlipidemia, and arterial hypertension are usual complications after LT, all negatively affecting the quality of life, morbidity, and patient and graft survival\textsuperscript{[19]}.

In the context of metabolic impairment, CV disorders are the chief causes of death unrelated to liver illness, being the third most usual cause of mortality in LT recipients (12\%-16\% of deaths)\textsuperscript{[19]}.

Notably, the role of immunosuppressant drugs is relevant. Considering that all immunosuppressant drugs negatively influence both glycemic and lipid metabolism, it is not surprising that transplanted subjects develop metabolic disorders with major prevalence and incidence with respect to the general population\textsuperscript{[21]}.

In this setting, both recurrent and \textit{de novo} NAFLD/NASH are common post-transplant complications\textsuperscript{[22]}

Here, we analyze the main challenges of NAFLD/NASH in both pre-and post-LT periods.

**METHODS**

We prepared a non-systematic review article with the following electronic sources: PubMed, MEDLINE, Google Scholar, Ovid, Scopus, and Web of Science. We used the following search words: “non-alcoholic steatohepatitis”, “liver transplant”, “diabetes”, “metabolic syndrome”, and “cardiovascular risk” alone or in combination with “outcome”, “epidemiology”, and “graft survival”. We considered all papers reporting human-related data (inclusion criteria), excluding articles with unavailable full text, not in the English language, abstracts, book chapters, and articles published before 1990 (exclusion criteria). Finally, we analyzed supplementary references/articles among manuscripts considered in the first research.

**PRE- AND POST-TRANSPLANT METABOLIC DISORDERS**

**Obesity**

Obesity is commonly associated with NASH in its progressive form\textsuperscript{[9]}. However, the role of obesity as an outcome predictor for LT candidates is debated. Nair \textit{et al.}\textsuperscript{[23]} clearly reported that severe obesity (BMI ≥ 40 kg/m\textsuperscript{2}) represents a strong independent predictor of post-LT mortality. Conversely, Leonard \textit{et al.}\textsuperscript{[24]} stated that adjusting the body mass index (BMI) for ascites does not correlate with post-LT outcomes. In any case, several authors suggested that obesity can be related to an increased percentage of early graft dysfunction, longer hospital stays and increased infection risk\textsuperscript{[23,25,26]}. Furthermore, Segev \textit{et al.}\textsuperscript{[27]} reported that candidates with obesity were more likely to be excluded from the organ allocation than leaner ones.

Since the prognosis of obese patients seems to be significantly affected by the concomitant presence of diabetes\textsuperscript{[28]}, the International Liver Transplantation Consensus Statement recommends an accurate selection of NASH candidates, especially if more than one comorbidity is diagnosed\textsuperscript{[29]}

Van Son \textit{et al.}\textsuperscript{[30]} reported that one year from transplant, 44\% of patients became obese. Obesity registered one year after OLT determined a two-fold risk of mortality, representing a strong predictor of in the very
long-term follow-up. In fact, BMI was contrariwise related to 15-year patient survival (HR 1.08, 95% CI 1.03-1.14, \(P = 0.001\) per kg/m\(^2\), independently of many patterns such as age, gender, and CV risk profile.

Obesity represents one major negative issue for transplanted patients since subjects with BMI > 30 show poorer patient and graft survival than normal-weight recipients (72.6% vs. 69.8% and 75.8% vs. 85.4%, respectively)\(^{[31]}\). Obesity and type 2 diabetes together increased the 30-day risk of post-surgery complications, the extent of hospital stay, and reduced graft survival\(^{[32]}\). Post-LT diabetes alone increases the risk of graft rejection and patient mortality\(^{[33]}\). Nair et al.\(^{[23]}\) confirmed the above-reported data by revising the UNOS data from 1988 to 1996. They described a rise in primary graft non-function and an increase of one-month, one-year, and two-year mortality in morbidly obese LT recipients.

The greater mortality risk and the higher early postoperative complications, mostly due to cardiopulmonary complications in obese patients, were definitively confirmed by a meta-analysis (on 132,162 subjects)\(^{[34]}\).

Starting from these clear data, both the American Association for the Study of Liver Disease and European Association for the Study of the Liver stated that severely obese patients should be carefully studied before LT and that high-degree obesity (BMI > 40 kg/m\(^2\) for North America and BMI > 35 kg/m\(^2\) for Europe) can represent a relative contraindication for LT itself\(^{[1,35]}\).

Further developing primary and secondary prevention strategies (i.e., early diet, lifestyle modification, and in selected cases, the bariatric surgery approach) against obesity should be mandatory.

**Diabetes**

The prevalence of diabetes amongst subjects awaiting LT for NASH ranges from 46% to 55%\(^{[35,36]}\). Considering the pre-LT context, diabetes is associated with early postoperative complications, such as infection and adverse CV events\(^{[37]}\). Moreover, we recently demonstrated that pre-LT diabetes represents an independent predictor of post-transplant atherosclerotic events and CV-related mortality\(^{[38]}\).

Pre-transplant diabetes, frequently associated with NASH, is related to worse post-LT outcomes since it increases the risk of portal venous thrombosis and consequently the three-month post-LT mortality\(^{[32,39]}\).

Notably, diabetes, together with recipient age, Model for End-Stage Liver Disease score (MELD), BMI, and dialysis before LT, is a chief predictor for 90-day post-LT mortality\(^{[40]}\).

Insulin resistance and diabetes, which are often diagnosed in the pre-LT period, tend to improve the following LT, but the high incidence of post-LT metabolic syndrome and the use of immunosuppressive drugs favor diabetes recurrence or new-onset diabetes after transplant (NODAT)\(^{[41,42]}\). Notably, calcineurin inhibitors (CNIs) (tacrolimus and cyclosporine) are the main risk factors for post-LT diabetes\(^{[41,42]}\). Markedly, the incidence of NODAT at 12 and 60 months is about 25% and 18%, respectively\(^{[41,42]}\). The incidence becomes higher and higher the closer we get to the transplant, reaching 44% at three months\(^{[41,42]}\).

Advanced age, ethnicity, family history, body mass index, hepatitis C virus infection, and immunosuppressive drugs such as corticosteroids and tacrolimus all are main risk factors for post-LT diabetes\(^{[41,42]}\). A BMI ≥ 30 kg/m\(^2\) is related to an augmented risk for diabetes\(^{[41,42]}\).
NODAT negatively impacts the recipient’s long-term survival, similarly to pre-LT disease. Notably, LT recipients developing NODAT show a worse overall survival and a major incidence of both infection and chronic renal failure\(^{[41,42]}\).

**KIDNEY DISEASE BEFORE AND AFTER TRANSPLANT**

Patients with NASH usually show several risk factors for chronic kidney disease (CKD)\(^{[35,43,44]}\). Indeed, it is not surprising that CKD prevalence among these patients is high, ranging from 20% to 55%\(^{[35,43,44]}\).

Interestingly, NASH can also lead to an increased risk of CKD after adjusting for the presence of diabetes\(^{[45]}\). Additionally, in patients with diabetes-related kidney disease, NASH represents a strong risk factor for CV events\(^{[46]}\). Remarkably, in patients with NASH, CKD was associated with decreased global survival\(^{[47]}\).

The existence of CKD before LT represents a consolidated risk factor for post-LT renal damage, being associated with a decrease in both graft and patient survival\(^{[48,49]}\). Candidates for NASH-related cirrhosis, particularly if in end-stage liver disease, are more prone to require renal replacement therapy before LT in comparison with other main indications, and this leads to a significant increase in pre-LT mortality risk (+150%)\(^{[50,51]}\).

Female sex, pre-transplant CKD, and NASH are strong and independent predictors of post-LT CKD (stage ≥ III)\(^{[50]}\). Considering patients transplanted for NASH, subjects with normal pre-LT renal function show a lower risk of death and increased graft survival than those with pre-LT severe renal dysfunction\(^{[52]}\). NASH patients undergoing LT develop a significant reduction of glomerular filtration rate after three months from LT in comparison with non-NASH candidates. Interestingly, the renal impairment tends to persist also after adjustments for body weight, diabetes, tacrolimus, hypertension, and HCC\(^{[53]}\).

The renal condition is a very important point in the management of LT recipients since the main immunosuppressant drug category (calcineurin inhibitors) shows well-known nephrotoxicity\(^{[1]}\). Indeed, patients with NASH deserve particular attention, and newly defined protocols to minimize the calcineurin inhibitor dosages in this specific subgroup of recipients should be implemented.

**CARDIOVASCULAR RISK AND PRE-TRANSPLANT SCREENING**

Patients with NASH awaiting LT require specific clinical attention\(^{[54]}\). In fact, candidates with NASH often show a clinical phenotype of metabolic syndrome and a noteworthy prevalence of CV events\(^{[55]}\).

The pathogenesis of CV disease in patients with NASH is multifactorial. Besides the “classic” risk factors such as hypertension, hyperlipidemia, and impaired glucose tolerance, a typical NASH-related endothelial dysfunction has been described\(^{[56,57]}\).

Considering the metabolic, CV, and renal impairment of patients with NASH awaiting LT, an accurate CV risk stratification is mandatory\(^{[20]}\).

Before LT, all patients are subjected to a transthoracic echocardiogram to evaluate both structural and functional heart capacity. In the absence of consolidated protocols, some authors proposed that subjects who show more than two CV risk factors (age > 50 years, hypertension, hyperlipidemia, and obesity) should also receive stress testing\(^{[51]}\). Obviously, coronary angiography should be a further step in patients with
altered stress tests\textsuperscript{[58]}. 

Furthermore, pre-transplant percutaneous coronary intervention and revascularization are needed in obstructive coronary artery disease (\(> 50\%\) reduction in luminal diameter of major coronaries). On the contrary, medical management with beta-blockers and statins might be enough in candidates with non-obstructive diseases\textsuperscript{[59]}. 

The relevance of pre-LT CV assessment is determined by the great transplant-related cardiac stress. In fact, during LT, acute CV changes, including the reduced venous return and an abrupt upsurge in peripheral vascular resistance, can be registered. Moreover, hemorrhage and reperfusion syndrome can complicate the hemodynamic situation\textsuperscript{[60]}. 

**POST-TRANSPLANT OUTCOMES**

**Survival**

According to the European Liver Transplant Registry, patients with NASH show a post-LT survival comparable to other aetiologies\textsuperscript{[14]}. In particular, there was no substantial variance between NASH and non-NASH recipients, nor for subjects with or without evidence of HCC\textsuperscript{[14]}. Among patients without HCC, NASH showed equivalent post-LT survival in comparison with alcohol-related disease and higher survival with respect to hepatitis C virus (HCV)\textsuperscript{[14]}. Considering patients with a diagnosis of HCC, survival in recipients with NASH was slightly poorer than alcohol-related liver disease, but it was comparable to HCV\textsuperscript{[14]}. Despite the overall data, factors typically associated with NASH, such as age \(> 60\) years, BMI \(\geq 30\) kg/m\(^2\), and diabetes, are well-consolidated risk factors for both 1- and 12-month mortality after LT\textsuperscript{[55]}. 

**Post-transplant cardiovascular risk**

CV disease is the foremost reason for death among LT recipients since it accounts for 19-42\% of non-graft-related mortality\textsuperscript{[61]}. Rubin\textsuperscript{et al.}\textsuperscript{[62]} analyzed the outcome of LT recipients surviving at least 10 years from LT. Among 323 LT recipients, 52\% were alive \(> 10\) years post-LT. Twenty-seven CV events occurred in 27 patients (17\%), between 0.18 and 8.1 years post-LT (median 3.1 years), with 1-, 3-, 5-, and 10-year cumulative rates from baseline of 2\%, 5\%, 10\%, and 17\%, respectively. 

Diabetes, hypertension, renal dysfunction, and NASH represent consolidated risk factor for post-LT CV disorders\textsuperscript{[61,63,64]}. In particular, patients with pre-LT NASH show a higher risk of CV- and cerebrovascular-related mortality, especially in the first year after LT, if compared to candidates with other indications\textsuperscript{[61,66]}. 

Pre-LT diabetes and kidney disease are other important predictors of post-LT CV mortality\textsuperscript{[60]}. Notably, we recently demonstrated through a multicenter cohort study that pre-transplant diabetes represents the major risk factor for both post-LT atherosclerotic vascular events and CV mortality\textsuperscript{[38]}. 

Immunosuppressive regimes show a key role in influencing the CV risk of LT recipients\textsuperscript{[31]}. 

Fussner\textsuperscript{et al.}\textsuperscript{[67]} analyzed the CV risk factors with a retrospective study involving 455 transplanted patients with a considerable follow-up period (8-12 years). Notably, CV disease was diagnosed in 10.6\%, 20.7\%, and 30.3\% of patients at one, five, and eight years from transplant, respectively. In the multivariate analysis, age, diabetes, history of CV disorder, pre-LT troponin level (\(> 0.07\) ng/mL), and tacrolimus use vs. “other” (hazard ratio, 0.26; 95\%CI: 0.14-0.49; \(P < 0.001\)) emerged as independent predictors of CV risk in the post-LT phase. The authors underlined that the potential CV benefit of tacrolimus should be confirmed with further prospective studies.
The role of steroids, widely used in the first period after transplant, is important. In fact, considering the general population, high-dose steroids are consolidated risk factors for both steatosis and metabolic impairment. However, in the post-LT, most specialists taper steroids over 1-6 months, and consequently, their effects on the long-term outcome might be marginal. However, the total daily dose of steroid treatment seems to be strongly correlated with the risk of post-LT metabolic syndrome\[68\]. Interestingly, in the last years, steroid-free protocols have been proposed to achieve a relevant decrease in diabetes and hyperlipidemia incidence\[69\].

Gilad et al.\[70\] developed a retrospective study involving 52 LT recipients who received mTOR inhibitors. They demonstrated that a kidney function improvement was observed without a significant weight gain or new-onset diabetes mellitus. However, they reported a few upsurges in total cholesterol (+7 mg/dL) and blood pressure. In general, treatment with mTOR inhibitors does not seem to lead to a noteworthy metabolic impairment, representing a good option, especially if a metabolic risk profile is present (i.e., NASH as transplant indication).

Among CNIs, tacrolimus is better than cyclosporine in terms of metabolic impact. In fact, post-transplant deaths and re-transplantation rates are higher in patients treated with cyclosporine compared to subjects on tacrolimus therapy. Moreover, patients on cyclosporine more often developed hypertension and hyperlipidemia than those in the tacrolimus group\[71,72\].

It is important to act on modifiable CV risk factors, such as hypertension, diabetes, dyslipidemia, and smoking. Hyperlipidemia, in particular, is very common after LT, affecting up to 71% of subjects. The best approach for the treatment of hyperlipidemia might be starting with lifestyle modification, then optimization of the dose and/or type of immunosuppressive drugs, and finally, the use of lipid-lowering agents (with particular attention to the possible drug interactions)\[73\].

**Post-transplant NAFLD/NASH**

Considering the high prevalence of metabolic disorders after LT, it is not surprising that both recurrent and de novo NAFLD/NASH can often be diagnosed.

De novo NAFLD and NASH can be detected in 26% and 2% of patients, respectively\[74\], while NASH recurrence ranges from 20% to 40% of cases\[75\].

Diabetes, hypertension, hyperlipidemia, renal dysfunction, and weight gain represent the major adjustable risk factors for the development of de novo and recurrent NAFLD, while age, genetics (i.e., PNPLA3), sex, and pre-existing CV disease are the most relevant non-modifiable ones\[76-82\].

Vallin et al.\[83\], in a biopsy-based study, and Narayanan et al.\[84\], in an ultrasound study, demonstrated that recurrent NAFLD and de novo NAFLD are different conditions with different prognoses. Recurrent NAFLD seems to be more severe and clinically aggressive and with earlier onset in comparison with de novo NAFLD. Narayanan et al.\[84\] described allograft steatosis in 78% of subjects transplanted for NASH and in 44% of patients with other indications. Patients with a recurrent form showed a more rapid fibrosis progression to cirrhosis within five years, and liver disease is more often associated with CV events.

**CONCLUSION**

As summarized in Table 1, metabolic impairment of both pre- and post-LT periods represents a very complex matter.
Table 1. Main key messages about the metabolic disorders of both pre- and post-transplant period

| Key message                                                                 | Ref.          |
|----------------------------------------------------------------------------|---------------|
| **Pre-LT**                                                                 |               |
| Increased risk of developing HCC                                           | [12,13]       |
| High prevalence of diabetes mellitus                                      | [35,36]       |
| CKD is a frequent comorbidity and is associated with poor outcome         | [35,43,44,46,47,50,51] |
| Increased prevalence of CVE                                               | [55]          |
| Obesity is a strong predictor of mortality, graft dysfunction, longer hospital stay, infection | [23,25,26,30] |
| Diabetes mellitus increases the risk of portal vein thrombosis and mortality | [32,39,40] |
| NODAT negatively impacts the overall survival, increasing infection and CKD risk | [41,42]       |
| CKD is associated with post-LT renal damage, decreasing both graft and patient survival | [48,49,52]   |
| Significant reduction of renal function after 3 months from LT            | [53]          |
| CVE accounts for most of the non-graft related mortality                   | [61,62,67]    |
| **Post-LT**                                                                |               |
| Optimization of immunosuppression is a chief part of therapy against metabolic impairment | [69,70,73]   |

HCC: Hepatocellular carcinoma; CKD: chronic kidney disease; CVE: cardiovascular events; NODAT: new-onset diabetes after transplant; LT: liver transplantation; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis

Patients undergoing LT for NASH represent a substantial challenge for transplant specialists due to the simultaneous presence of liver disease and systemic metabolic disorders. Before LT, a multidisciplinary team including cardiologists, nephrologists, diabetologists, nutritionists, and anesthesiologists should act to decrease the metabolic impairment as much as possible and to stratify the intra- and perioperative risks of patients to confirm the transplant feasibility. Interestingly, Moura et al. proposed a similar team concept for transplanted patients with nutritionists and diabetologists who might work together with surgeons.

Early after LT, recipients should be thoroughly informed and educated to avoid uncontrolled weight gain. Supervised diet and exercise programs should be recommended to all patients after LT, especially those with major metabolic risk factors and/or poor functional capacity. Furthermore, early adaptation of an immunosuppressive regimen should be implemented to decrease the cardio-metabolic risk as well as to reduce the risk of CKD.

Further studies should clarify the impact of CV events on the recipients’ survival. In fact, patients with pre-LT NASH show a higher risk of those events and a long-term survival comparable to or better than other aetiologies.

**DECLARATIONS**
**Authors’ Contributions**
Made a substantial contribution in writing-original draft preparation, to the design of the work, the acquisition, analysis, and interpretation of data: Gitto S, Mannelli N
Made a substantial contribution in critically review and editing the work: Andreone P, Nascimbeni F, Tassi A, Gabrielli F
Supervisor: Andreone P

**Availability of data and materials**
Not applicable.
Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016;64:433-85. DOI
2. Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical updates on chronic hepatitis B virus infection in 2021. Cireus 2021;13:e19152. DOI PubMed PMC
3. Younasfzai MT, Bajis S, Alavi M, Grebely J, Dore GJ, Hajarizadeh B. Global cascade of care for chronic hepatitis C virus infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:1340-54. DOI PubMed
4. Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: disease burden, current management and future challenges. JHEP Rep 2020;2:100192. DOI PubMed PMC
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. DOI PubMed
6. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-8. DOI PubMed
7. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202-9. DOI PubMed PMC
8. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1. DOI PubMed
9. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-530.e1; quiz e60. DOI PubMed PMC
10. Cotter TG, Charlton M. Nonalcoholic steatohepatitis after liver transplantation. Liver Transpl 2020;26:141-59. DOI PubMed
11. Adam R, Karam V, Caillez V, et al; all the other 126 contributing centers (www. eltr.org) and the European Liver and Intestine Transplant Association (ELITA). 2018 annual report of the European liver transplant registry (ELTR)-50-year evolution of liver transplantation. Transpl Int 2018;31:1293-317. DOI PubMed
12. Kolly P, Dufour JF. Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics (Basel) 2016;6:22. DOI PubMed PMC
13. Younossi Z, Stepanova M, Ong JP, et al; Global nonalcoholic steatohepatitis council. nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-755.e3. DOI PubMed
14. Haldar D, Kern B, Hodson J, et al; European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a european liver transplant registry study. J Hepatol 2019;71:313-22. DOI PubMed PMC
15. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188-95. DOI PubMed
16. Axley P, Ahmed Z, Arora S, et al. NASH is the most rapidly growing etiology for acute-on-chronic liver failure-related hospitalization and disease burden in the united states: a population-based study. Liver Transpl 2019;25:695-705. DOI PubMed
17. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31. DOI PubMed
18. Parikh ND, Marrero WJ, Wang J, et al. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology 2019;70:487-95. DOI PubMed
19. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10:1420-7. DOI PubMed PMC
20. Ferreira SC, Penaforte FRO, Cardoso ASR, et al. Eating behaviour patterns are associated with excessive weight gain after liver
transplantation. *J Hum Nutr Diet* 2019;32:693-701. DOI PubMed
21. Charco R, Cantarell C, Vargas V, et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. *Liver Transpl Surg* 1999;5:204-8. DOI PubMed
22. Bhagat V, Minkogiou AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. *Liver Transplant* 2009;15:1814-20. DOI PubMed
23. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. *Hepatology* 2002;35:105-9. DOI PubMed
24. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. *Am J Transplant* 2008;8:667-72. DOI PubMed
25. Hakeem AR, Cockburn AJ, Raza SS, et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. *Liver Transplant* 2013;19:551-62. DOI PubMed
26. Singhal A, Wilson GC, Wima K, et al. Impact of recipient morbidity on outcomes after liver transplantation. *Transpl Int* 2015;28:148-55. DOI PubMed
27. Segev DL, Thompson RE, Locke JE, et al. Prolonged waiting times for liver transplantation in obese patients. *Ann Surg* 2008;248:863-70. DOI PubMed
28. Conzen KD, Vachharajani N, Collins KM, et al. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. *HPB (Oxford)* 2015;17:251-7. DOI PubMed PMC
29. Tschochatzis E, Coilly A, Nadalin S, et al. International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation. *Transplantation* 2019;103:45-56. DOI PubMed
30. van Son J, Stam SP, Gomes-Neto AW, et al. Post-transplant obesity impacts long-term survival after liver transplantation. *Metabolism* 2020;106:154204. DOI PubMed
31. Beckmann S, Drent G, Rappar T, Nikolic N, De Geest S. Body weight parameters are related to morbidity and mortality after liver transplantation: a systematic review and meta-analysis. *Transplantation* 2019;103:2287-303. DOI PubMed
32. Dure AJ, Plank LD, Phillips AR, et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. *Liver Transpl* 2014;20:281-90. DOI PubMed
33. Lieber SR, Lee RA, Jiang Y, et al. The impact of post-transplant diabetes mellitus on liver transplant outcomes. *Clin Transplant* 2019;33:e13554. DOI PubMed PMC
34. Barone M, Viggiani MT, Losurdo G, Principi M, Leandro G, Di Leo A. Systematic review with meta-analysis: post-operative complications and mortality risk in cadaveric liver transplant candidates with obesity. *Aliment Pharmacol Ther* 2017;46:236-45. DOI PubMed
35. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology* 2015;148:547-55. DOI PubMed
36. O’Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. *Clin Gastroenterol Hepatol* 2011;9:700-704.e1. DOI PubMed PMC
37. Trull KC, Stratta RJ, Larsen JL, et al. Results of liver transplantation in diabetic recipients. *Surgery* 1993;114:650-6; discussion 656. DOI PubMed
38. Gittos S, De Maria N, Marzi L, et al; other members of MEDITRA research group. Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. *Eur J Intern Med* 2020;79:70-5. DOI PubMed
39. Eshraghian A, Nikieghbalian S, Kazemi K, et al. Portal vein thrombosis in patients with liver cirrhosis and its impact on early and long-term outcomes after liver transplantation. *Int J Clin Pract* 2018;e13309. DOI PubMed
40. Molinari M, Ayloo S, Tsung A, et al. Prediction of perioperative mortality of cadaveric liver transplant recipients during their evaluations. *Transplantation* 2019;103:e297-307. DOI PubMed PMC
41. Saliba F, Lakehal M, Pageaux GP, et al; Diapason Study Group. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. *Liver Transplant* 2007;13:136-44. DOI PubMed
42. Kuo HT, Sampaoio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the organ procurement and transplant network/united network for organ sharing database. *Transplantation* 2010;89:1134-40. DOI PubMed
43. Park CW, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. *Clin Transplant* 2011;25:E606-11. DOI PubMed
44. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. *Am J Kidney Dis* 2014;64:638-52. DOI PubMed
45. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. *PLoS Med* 2014;11:e1001680. DOI PubMed PMC
46. Chinnadurai R, Chrysochoou C, Kalra PA. Increased risk for cardiovascular events in patients with diabetic kidney disease and non-alcoholic fatty liver disease. *Nephron* 2019;141:24-30. DOI PubMed
47. Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. *Liver Int* 2019;39:342-52. DOI PubMed
48. Fussner LA, Charlton MR, Heimbach JK, et al. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. *Liver Int* 2014;34:1259-66. DOI PubMed
49. Ramachandran J, Juncia R, John L, et al. Chronic kidney disease following liver transplantation: a South Australian experience. *Transplant Proc* 2010;42:3644-6. [DOI](https://doi.org/10.1016/j.transproceed.2010.06.154) [PubMed]

50. VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. *Liver Int* 2015;35:2575-83. [DOI](https://doi.org/10.1002/lt.24616) [PubMed] [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706573/)

51. Agopian VG, Kaldas FM, Hong JC, et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. *Ann Surg* 2012;256:624-33. [DOI](https://doi.org/10.1097/SLA.0b013e318259136f) [PubMed]

52. Molnar MZ, Joglekar K, Jiang Y, et al; Global NAFLD Consortium. Association of pretransplant renal function with liver graft and patient survival after liver transplantation in patients with nonalcoholic steatohepatitis. *Liver Transpl* 2019;25:399-410. [DOI](https://doi.org/10.1002/lt.25202) [PubMed] [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088034/)

53. Houlihan DD, Armstrong MJ, DavidoV Y, et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? *Liver Transpl* 2011;17:1292-8. [DOI](https://doi.org/10.1002/lt.22560) [PubMed]

54. Sharma S, Stine JG, Verbeek T, Bezinover D. Management of patients with non-alcoholic steatohepatitis undergoing liver transplantation: considerations for the anesthesiologist. *J Cardiothorac Vasc Anesth* 2021;S1053-0770(21)00601. [DOI](https://doi.org/10.1002/jcva.100601) [PubMed]

55. Malik SM, deVer Me, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. *Am J Transplant* 2009;9:782-93. [DOI](https://doi.org/10.1111/j.1600-6143.2009.03187.x) [PubMed]

56. Pastori D, Loffredo L, Perri L, et al. Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors. *Am J Cardiol* 2015;115:1402-6. [DOI](https://doi.org/10.1016/j.amjcard.2014.12.097) [PubMed]

57. Kim BI, Kim NH, Kim BS, Kang JH. The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals. *Cardiology* 2012;123:54-61. [DOI](https://doi.org/10.1159/000346484) [PubMed]

58. Patel SS, Nabi E, Guzman L, et al. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. *Liver Transpl* 2018;24:333-42. [DOI](https://doi.org/10.1002/hep.29637) [PubMed]

59. van Kuijk JP, Flu WJ, Schouten A, et al. Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents. *Am J Cardiol* 2009;104:1229-34. [DOI](https://doi.org/10.1016/j.amjcard.2009.08.004) [PubMed]

60. Liu H, Jayakumar S, Traboulsi M, Lee SS. Cirrhotic cardiomyopathy: Implications for liver transplantation. *Liver Transpl* 2017;23:826-35. [DOI](https://doi.org/10.1002/lt.24543) [PubMed]

61. Laruea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. *Liver Transpl* 2007;13:1109-14. [DOI](https://doi.org/10.1002/lt.21005) [PubMed]

62. Rubin A, Sánchez-Montes C, Aguilera V, et al. Long-term outcome of “long-term liver transplant survivors”. *Transpl Int* 2013;26:740-50. [DOI](https://doi.org/10.1111/tci.12057) [PubMed]

63. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. *Clin Gastroenterol Hepatol* 2012;10:646-50. [DOI](https://doi.org/10.1016/j.cgh.2011.10.021) [PubMed]

64. Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. *Int J Endocrinol* 2013;2013:124958. [DOI](https://doi.org/10.1155/2013/124958) [PubMed] [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797253/)

65. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014;12:394-402.e1. [DOI](https://doi.org/10.1016/j.cgh.2013.12.007) [PubMed]

66. Nagai S, Collins K, Chau LC, et al. Increased risk of death in first year after liver transplantation among patients with nonalcoholic steatohepatitis vs liver disease of other etiologies. *Clin Gastroenterol Hepatol* 2019;17:2759-2768.e5. [DOI](https://doi.org/10.1016/j.cgh.2019.06.033) [PubMed]

67. Fussner LA, Heimbach JK, Fan C, et al. Cardiovascular disease after liver transplantation: when, what, and who is at risk. *Liver Transpl* 2015;21:889-96. [DOI](https://doi.org/10.1002/lt.24116) [PubMed]

68. Sprinzl MF, Weinmann A, Lohe N, et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. *Transpl Int* 2013;26:67-74. [DOI](https://doi.org/10.1111/txi.12007) [PubMed]

69. Sgourakis G, Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review. *World J Gastroenterol* 2014;20:10703-14. [DOI](https://doi.org/10.3748/wjg.v20.i33.10703) [PubMed] [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308369/)

70. Gilad O, Rabinovich L, Levy S, et al. Metabolic and renal effects of mammalian target of rapamycin inhibitors treatment after liver transplantation: real-life single-center experience. *Transplant Proc* 2021;53:221-7. [DOI](https://doi.org/10.1016/j.transproceed.2021.02.061) [PubMed]

71. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. *Liver Transpl* 2008;14:1648-54. [DOI](https://doi.org/10.1002/lt.21336) [PubMed]

72. O’grady J, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. *The Lancet* 2002;360:1119-25. [DOI](https://doi.org/10.1016/S0140-6736(02)08752-4) [PubMed]

73. Hüsing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. *World J Gastroenterol* 2016;22:3315-24. [DOI](https://doi.org/10.3748/wjg.v22.i19.3315) [PubMed] [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019474/)

74. Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: de novo nonalcoholic fatty liver disease in liver-transplanted patients. *Aliment Pharmacol Ther* 2018;47:704-14. [DOI](https://doi.org/10.1111/apt.14893) [PubMed]

75. Burra P, Germani G. Orthotopic liver transplantation in non-alcoholic fatty liver disease patients. *Rev Recent Clin Trials* 2014;9:210-6. [DOI](https://doi.org/10.2174/18747560014999990210) [PubMed]

76. Tokodai K, Karadagi A, Kjaeremet F, Romano A, Ericzon BG, Nowak G. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation. *Scand J Gastroenterol* 2019;54:233-9. [DOI](https://doi.org/10.1080/00365521.2018.1478676) [PubMed]

77. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. *Liver Transpl* 2001;7:797-801. [DOI](https://doi.org/10.1002/ltp.10023) [PubMed]

78. El AttaChe MM, Abouljoud MS, Divine G, et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following
orthotopic liver transplantation in the context of the metabolic syndrome. *Clin Transplant* 2012;26:E505-12. DOI PubMed

79. Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. *Am J Gastroenterol* 2010;105:613-20. DOI PubMed

80. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. *Am J Transplant* 2004;4:686-93. DOI PubMed

81. Hübscher SG. Transplantation pathology. *Semin Liver Dis* 2009;29:74-90. DOI PubMed

82. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. *Liver Transpl* 2010;16:431-9. DOI PubMed

83. Vallin M, Guillaud O, Boillot O, Hervieu V, Scoazec JY, Dumortier J. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. *Liver Transpl* 2014;20:1064-71. DOI PubMed

84. Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. *Transplantation* 2019;103:e14-21. DOI PubMed

85. Moura Neto A, Bovi TG, Righetto CM, et al. Clinical profile of patients with diabetes mellitus and liver transplantation: results after a multidisciplinary team intervention. *Transplant Proc* 2018;50:784-7. DOI PubMed